Boston pays off heart patients over Guidant ICD (implantable cardioverter defibrillators) debacle
This article was originally published in Clinica
Boston Scientific has agreed to fork out $195m to settle charges concerning acquired company Guidant's failure to warn heart patients about potential flaws in its implantable cardioverter defibrillators (ICDs).
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.